서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 32 of 32

Issue DateTitle / Author(s) / CitationFileAltmetrics
1998-01
A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-β type II receptor
DOI
1999-04
Truncation of the TGF-β type II receptor gene results in insensitivity to TGF-β in human gastric cancer cells
DOI
1999-10
Detection of methylation damage in DNA of gastric cancer tissues using P-32-postlabelling assay

Kim, Dae-Yong; Cho, Myung-Haing; Yang, Han-Kwang; Hemminki, Kari; Kim, Jin-Pok; Jang, Ja-June; Kumar, Rajiv

Japanese Journal of Cancer Research, Vol.90 No.10, pp.1104-1108

1999-12
Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer
DOI
2004-02
Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer
DOI
2008-02
Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer
DOI
2008-07
Randomized controlled trial comparing gastrectomy plus chemotherapy with chemotherapy alone in advanced gastric cancer with a single non-curable factor: Japan clinical oncology group study JCOG 0705 and korea gastric cancer association study KGCA01
DOI
2009-04
Functional links between clustered microRNAs: Suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer
view fileDOI
2009-07
Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer
DOI
2010-06
P-cadherin expression in gastric carcinoma: its regulation mechanism and prognostic significance
DOI
2011-02
Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study
DOI
2011-06
Clinicopathologic characteristics of patients with stage III/IV (M 0) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization
DOI
2011-11
Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma

Kim, Min A.; Lee, Hyuk-Joon; Yang, Han-Kwang; Bang, Yung-Jue; Kim, Woo Ho

Histopathology, Vol.59 No.5, pp.822-831

DOI
2012-01
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
DOI
2013-04
Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases
DOI
2013-06
Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer
DOI
2014-01
Ataxia-telangiectasia-mutated protein expression with microsatellite instability in gastric cancer as prognostic marker
DOI
2014-11
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
DOI
2016-03
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): A phase 3, randomised controlled trial
DOI
2016-04
Is there any role of adjuvant chemotherapy for T3N0M0 or T1N2M0 gastric cancer patients in stage II in the 7th TNM but stage I in the 6th TNM system?
DOI
2017-06
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
DOI
2020-07
microRNA-30a arbitrates intestinal-type early gastric carcinogenesis by directly targeting ITGA2
DOI
2021-01
Development of a Novel Orthotopic Gastric Cancer Mouse Model
view fileDOI
2021-04
Correction to: Development of a Novel Orthotopic Gastric Cancer Mouse Model (Biological Procedures Online, (2021), 23, 1, (1), 10.1186/s12575-020-00137-1)
DOI
2022-04
Short-Term Outcomes of Laparoscopic Proximal Gastrectomy With Double-Tract Reconstruction Versus Laparoscopic Total Gastrectomy for Upper Early Gastric Cancer: A KLASS 05 Randomized Clinical Trial
DOI
2022-04
Short-term Outcomes of Pylorus-Preserving Gastrectomy for Early Gastric Cancer: Comparison Between Extracorporeal and Intracorporeal Gastrogastrostomy
DOI
2022-05
Expression-based species deconvolution and realignment removes misalignment error in multispecies single-cell data
DOI
2022-08
Systematic review of gastric cancer-associated genetic variants, gene-based meta-analysis, and gene-level functional analysis to identify candidate genes for drug development
DOI
2022-10
In vivo and autopsy validation of alpha-synuclein seeding activity using RT-QuIC assay in the gastrointestinal tract of patients with Parkinson's disease
DOI
2022-10
Dysplastic Stem Cell Plasticity Functions as a Driving Force for Neoplastic Transformation of Precancerous Gastric Mucosa
DOI
2023-05
Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment
DOI
2023-09
Long-term outcomes of a phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumors of the stomach
DOI
1